SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MorphoSys AG (MOR)
An SI Board Since January 2000
Posts SubjectMarks Bans
421 15 0
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Compact
This stock has exploded since announcing that it licensed patents from Biosite.

Trades as MOR on Frankfurt Neuer Market.

Company web site is:
morphosys.com

For a similar EuroBioTech see Cambridge Antibody Systems (CAT on the London Stock Exchange).

Comments from those who follow this company?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
421 MorphoSys Receives Two Phase 2 Milestone Payments from Janssen September 17,Germanecki-9/19/2013
420 MorphoSys Raises EUR 84 million in Private Placement September 19, 2013 / 9:Germanecki-9/19/2013
419Impressive! Approval in 2016?Germanecki-8/20/2013
418Basel, August 20, 2013 - Novartis announced today that the US Food and Drug Adminigel bates18/20/2013
417 MorphoSys Closes on the Alliance with Celgene for MOR202 and Increases FinanciGermanecki-8/13/2013
416"the propietery pipeline is shrinked" For those concerned about cashfnigel bates-8/6/2013
415Hi ghmm, after the two deals with GSK and Celegene, the propietery pipeline is sGermanecki-8/6/2013
414Yes congratulations Germanecki the company has done real well lately! I should ghmm-8/2/2013
413 MorphoSys AG Reports Results for the First Six Months of 2013 July 31, 2013 Germanecki-8/2/2013
412Hi mcbio, yes, a big deal. But still under clearance by the US antitrust authoriGermanecki-8/2/2013
411Co-promotion rights in Europe is a pretty big deal IMO. I don't think Genmamcbio17/7/2013
410Great Deal!Germanecki-7/1/2013
409 MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Celgene Corporationnigel bates16/27/2013
408 Novartis Sees MorphoSys Muscle-Atrophy Drug as Exciting By Eva von Schaper - MGermanecki-5/21/2013
407 MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin&Germanecki-5/21/2013
406 MorphoSys Announces First Scientific Publication on Novel Antibody Platform YlGermanecki-5/21/2013
405 MorphoSys AG Reports Results for the First Quarter of 2013 May 03, 2013 / 7:Germanecki-5/21/2013
404 MorphoSys Announces Clinical Milestone in Ophthalmology Program May 02, 2013Germanecki-5/21/2013
403 MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in B-cell AcuteGermanecki-5/21/2013
402The cost of caring for people with dementia is $157-215B a year and could doubleBocor14/4/2013
401FDA proposes to dramatically lower the bar on Alzheimer's drugs March 14,Germanecki-3/14/2013
400 MorphoSys AG Reports Results for Fiscal Year 2012 March 05, 2013 / 7:00 am, Germanecki-3/14/2013
399MorphoSys and Heptares Sign Alliance to Develop Antibody Therapeutics Targeting Germanecki-2/13/2013
398bigcharts.marketwatch.comGermanecki-2/8/2013
397 MorphoSys Receives First Patent on Novel Antibody Platform Ylanthia in the US Germanecki-2/8/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News